| |
Aspirin attenuates platelet activation and immune activation in HIV-infected subjects on antiretroviral therapy: A Pilot Study
|
| |
| |
Download the PDF here
JAIDS Journal of Acquired Immune Deficiency Syndromes: POST ACCEPTANCE, 12 February 2013
O'Brien, Meagan MD; Montenont, Emilie MS; Hu, Liang PhD; Nardi, Michael A. MA; Valdes, Vanessa BS; Merolla, Michael BS; Gettenberg, Gabrielle BS; Cavanagh, Karen RN; Aberg, Judith A. MD; Bhardwaj, Nina MD PhD; Berger, Jeffrey S. MD, MS
1 New York University, School of Medicine, Division of Infectious Diseases and Immunology, Cancer
Institute, NY, NY
2 Bellevue Hospital Center, New York City Health and Hospital Corporation, New York, NY
3 New York University, School of Medicine, Divisions of Cardiology and Hematology, New York, NY
4 New York University, School of Medicine, Department of Pediatrics, Divisions of Hematology and Oncology, Pathology, New York, NY
5 New York University, School of Medicine, Division of Infectious Diseases and Immunology, New York, NY
6 New York University, School of Medicine, Divisions of Pathology, Dermatology, Cancer Institute, New York, NY
Reported at Intl AIDS Conf last summer in DC, oral presentation.
IAC: Low-Dose Aspirin for Activation: Increased platelet activity and immune activation in HIV-positive subjects on antiretroviral therapy is attenuated with low-dose aspirin
http://www.natap.org/2012/IAS/IAS_86.htm
Aspirin Linked to Age-Related Eye Disorder
http://www.natap.org/2013/newsUpdates/012413_03.htm
Aspirin From Wikipedia, the free
encyclopedia.....http://en.wikipedia.org/wiki/Aspirin
"This small pilot study provides evidence that activated platelets may contribute to immune activation and inflammation in HIV infection. Importantly, this study also suggests that low-dose aspirin may be a potential intervention for HIV-infected subjects on ART to blunt platelet and immune activation and inflammation. ......Altogether we present new data that platelets from treated and virologically suppressed HIV-infected subjects are hyper-reactive spontaneously and in response to platelet-activating agonists. We show that one week of daily aspirin 81mg is effective in decreasing platelet activity in HIV-infected and uninfected controls........As this study was a small non-randomized open-label pilot study, future studies are needed to confirm and expand upon our findings......Previous studies have shown that immune activation in ART-treated HIV-infected subjects is higher than in uninfected control subjects but lower than in untreated HIV-infected subjects.....In accordance with prior studies, we found that immune activation is higher in HIV-infected subjects on ART than uninfected control subjects. HIV-infected subjects had significantly higher %CD4+HLADR+CD38+ lymphocytes than uninfected control subjects (median 8.95% vs. 4.4%, p=0.001) and there was a trend for higher %CD8+HLADR+CD38+ lymphocytes in HIV-infected than uninfected control subjects (median 9.98% vs. 6.95%, p=0.13). In response to one week of aspirin, there was a significant decrease in HIV-infected subjects' CD4+ HLADR+CD38+ lymphocytes (median 8.95% vs 6.81%, p=0.005) and CD8+HLADR+CD38+lymphocytes (median 9.98% vs 6.70%, p=0.015) but not in uninfected control subjects' CD4+HLADR+CD38+ lymphocytes (median 4.40% vs 4.19%) and CD8+HLADR+CD38+ lymphocytes (median 6.95% vs 6.42%) (Figure 2A, B)......Our data indicate that one week of low-dose aspirin 81 mg daily partly ameliorates the defect in TLR responsiveness in PBMCs from HIV-infected subjects.......Median levels of CRP, d-dimer, and IL-6 decreased non-significantly after one week of aspirin therapy (2.7mg/L [0.8, 3.9] vs. 2.2 mg/L [0.8-3.2]), (0.23 mcg/mL [0, 0.36] vs. 0.13 mcg/mL [0, 0.38]), and 2.03 pg/mL [1.18, 2.31] vs. 1.98 pg/mL [1.15, 3.68])......The formation of platelet monocyte aggregates in this assay was significantly abrogated by aspirin therapy, indicating that soluble plasma factors may play a role in platelet hyper reactivity and innate immune activation in HIV infection, which may be reversed by aspirin therapy (Figure 4)."
Abstract
Background: Mechanisms for increased cardiovascular risk in HIV-infected adults are incompletely understood, but platelet activation and immune activation leading to a pro-thrombotic state have been proposed as significant contributors. Aspirin has anti-platelet and immunomodulatory properties. We explored whether one week of low dose aspirin attenuates platelet activation and immune activation in HIV-infected and virologically suppressed adults on antiretroviral therapy (ART).
Methods: Platelet activation and immune activation were measured in HIV-infected subjects virologically suppressed on ART and controls before and after one week of low-dose aspirin.
Results: Compared to control subjects, HIV-infected subjects had increased platelet activation, as measured by spontaneous platelet aggregation and aggregation in response to adenosine diphosphate, collagen, and arachidonic acid (AA). Following aspirin therapy, percent aggregation decreased similarly in both HIV-infected and control subjects to all platelet agonists tested except aggregation in response to AA, which remained elevated in the HIV-infected group. HIV infected subjects exhibited increased markers of T-cell activation (CD38 and HLA-DR) and monocyte activation (sCD14), which decreased after one week of aspirin therapy. Moreover, leukocyte responses to Toll-like receptor stimulation were enhanced after one week of aspirin therapy. In vitro studies showed that HIV-plasma could activate healthy platelets, which in turn activated monocytes, implicating a direct role for activated platelets in immune activation.
HIV-1 (HIV) infected patients have an increased risk of ischemic cardiovascular events1-3,HIV-1 (HIV) infected patients have an increased risk of ischemic cardiovascular events1-3,HIV-1 (HIV) infected patients have an increased risk of ischemic cardiovascular events1-3,
Conclusions: Our data demonstrate that heightened platelet activation and immune activation in treated HIV disease are attenuated by one week of aspirin therapy. Aspirin should be further studied for its antithrombotic and immunomodulatory benefits in treated HIV disease.
INTRODUCTION
HIV-1 (HIV) infected patients have an increased risk of ischemic cardiovascular events1-3, but the pathogenic mechanisms underlying this risk remain elusive. Although antiretroviral therapy (ART) may contribute to cardiovascular risk due to its metabolic adverse effects2, HIV itself is an independent risk factor for cardiovascular events4-6. These increased events correlate with increased markers of immune activation and inflammation, suggesting that a heighted inflammatory state in HIV contributes to thrombosis. Heightened immune activation correlates with disease progression in untreated HIV infection7,8 and persists, albeit to a lesser degree, in ART-treated HIV-infected patients and correlates with cardiovascular disease9.
Mechanisms that link immune activation, inflammation, and increased risk of thrombotic cardiovascular disease in HIV infection are incompletely understood. Recent studies have implicated platelet activation as a possible link. Circulating platelets in HIV-infected subjects have heightened expression of P-selectin, a molecule which binds P-selectin glycoprotein ligand-1 on endothelium and leukocytes and acts to recruit these cells to areas of injury and thrombosis10. Circulating platelet-monocyte complexes, another marker of platelet activation, are also elevated in HIV-infected subjects11. Notably, ART-treated subjects were not differentiated from viremic untreated subjects in these studies10,16. It is therefore unknown whether ART-treated and virologically suppressed subjects also manifest heightened platelet activation. Activated platelets have been implicated in thrombotic cardiovascular events because of their proinflammatory and thrombogenic effects12 and clinical studies have demonstrated the importance of platelet activity in coronary artery atherosclerosis and thrombosis. Platelet activity, measured by spontaneous platelet aggregation, provides information about platelet function, and is independently associated with long-term mortality and cardiovascular events13. Antiplatelet therapy is a cornerstone in the prevention of atherothrombotic events and its effects likely involve the modulation of inflammatory and immune pathways12,14-16. Therefore, we conducted an exploratory study to assess whether low dose aspirin In HIV infected subjects virologically suppressed on ART would result in decreased platelet activity, immune activation and markers of inflammation.
RESULTS
Median age of HIV-infected was 50 (range, 31 to 71). Nearly 50% of the population was white and 76% were male. 56% were current smokers. Mean CD4+T cell count was 630 (range 181-1124), mean CD4+T cell count nadir was 166 (range 5-422). Mean years of HIV diagnosis was 9.5 (range 1-26) and mean years on effective ART therapy with a suppressed HIV RNA viral load was 6 (range 0.5-21). All subjects with HIV had platelet counts within the normal range (195x103/ml [IQR, 164, 241]). Current ART regimens are listed in Subject demographics.
ART-treated HIV-infected subjects have hyper-reactive platelets
Prior data20 demonstrate that the use of sub-maximal concentrations of agonists identify subjects with a hyper-reactive platelet phenotype. HIV-infected subjects evidenced significantly higher median spontaneous platelet aggregation (SPO) (7.9% [4.6, 11.8] vs 4.9% [2.4, 8.4], p=0.045) and higher median aggregation in response to all sub-maximal agonist concentrations (ADP 0.4uM, 11.3% [6.6, 44.4] vs 6.4% [2.8, 9.7], p=0.003; Collagen (COL) 0.05ug/ml, 5.6% [3.9, 12.4] vs 3.2% [1.8, 6.2], p=0.001; and AA 150uM, 54.9% [8.2, 89.9] vs 7.4% [3.0, 31.0], p=0.003) except epinephrine (EPI) 0.1uM 81.2% [17.0-91;3] vs 78.8% [13.0-90.7], p=0.672, than uninfected controls. At higher agonist concentrations, much of the differences observed between HIV infected subjects and healthy controls were attenuated (Table 1).
Effects of aspirin on platelet activity in ART-treated HIV-infected subjects
Platelet aggregation was measured 24 hours after a loading dose of aspirin 325mg in HIV-infected subjects and then again following one week of aspirin 81mg daily in both the HIV-infected subjects and the healthy controls. As compared to baseline, platelet aggregation was significantly inhibited following a single dose of 325mg in HIV-infected subjects and following one week of aspirin in both groups (controls were not available for single dose measurements) (see Table S1, Supplemental Digital Content, http://links.lww.com/QAI/A399). As compared to the control group, HIV-infected subject platelet aggregation was inhibited similarly after one week of aspirin to all platelet agonists tested except aggregation in response to low and high-dose AA, which remained elevated in the HIV-infected group (150uM, 9.7% [5.5, 15.2] vs 6.1% [4.5, 9.1], p=0.007, and AA 1500uM, 22.2% [16.4, 46.1] vs 12% [7.6, 21.7], p=0.002) (Table 1).
Urinary thromboxane is higher in HIV-infected subjects and is less responsive to aspirin therapy
Aspirin irreversibly acetylates platelet cyclooxygenase-1 (COX-1), inhibiting the formation of the potent platelet agonist thromboxane.To further assess platelet activity and the adequacy of COX-1 inactivation by aspirin ex vivo, we measured urinary excretion of the major enzymatic metabolite of thromboxane, 11-dehydro-thromboxane (TX) B2. The basal level of median urinary concentration of 11-dehydro thromboxane B2 was significantly higher in HIV-infected subjects compared with controls (9626.8 vs7295.2 pg/mL, p=0.02). After one week of aspirin, 11-dehydrothromboxane B2 decreased significantly in both groups but remained significantly higher in the HIV-infected group (2255.7 vs 1422.6 pg/mL, p=0.04) (Figure 1A).
ART-treated HIV-infected subjects have increased soluble P-selectin, which is decreased after a week of aspirin therapy
Soluble P-selectin (sP-selectin) is a biomarker for platelet/endothelial activation and is considered a risk factor for vascular disease21. sP-selectin enhances procoagulant activity by inducing leukocyte-derived microparticle production and promotes activation of leukocyte integrins. There was a trend for higher median sP-selectin in HIV-infected as compared to uninfected control subjects at baseline (58.2 ng/mL vs. 54.1 ng/mL) and a significant decrease in median sP-selectin in HIV-infected patients after one week of aspirin (58.2 ng/mL vs. 47.7ng/mL) but not after one day (58.2 ng/mL vs. 54.3 ng/mL)(Figure 1B).
T-cell and monocyte immune activation is higher in ART-treated HIV-infected subjects than uninfected control subjects and is decreased after one week of aspirin therapy
Previous studies have shown that immune activation in ART-treated HIV-infected subjects is higher than in uninfected control subjects but lower than in untreated HIV-infected subjects 22,23. Because aspirin has been shown to have immunomodulatory properties24,25, we tested whether aspirin may affect T-cell or monocyte activation markers. T cell activation was evaluated by measuring activation markers CD38 and HLA-DR on CD4+ and CD8+ lymphocytes. In accordance with prior studies, we found that immune activation is higher in HIV-infected subjects on ART than uninfected control subjects. HIV-infected subjects had significantly higher %CD4+HLADR+CD38+ lymphocytes than uninfected control subjects (median 8.95% vs. 4.4%, p=0.001) and there was a trend for higher %CD8+HLADR+CD38+ lymphocytes in HIV-infected than uninfected control subjects (median 9.98% vs. 6.95%, p=0.13). In response to one week of aspirin, there was a significant decrease in HIV-infected subjects' CD4+ HLADR+CD38+ lymphocytes (median 8.95% vs 6.81%, p=0.005) and CD8+HLADR+CD38+lymphocytes (median 9.98% vs 6.70%, p=0.015) but not in uninfected control subjects' CD4+HLADR+CD38+ lymphocytes (median 4.40% vs 4.19%) and CD8+HLADR+CD38+ lymphocytes (median 6.95% vs 6.42%) (Figure 2A, B).
Monocyte activation was tested by analyzing soluble CD14 (sCD14) levels in plasma. sCD14 levels were higher in treated HIV-infected subjects as compared to uninfected control subjects at baseline (median 2.60x106 vs 1.26x106 pg/mL; p<0.001) and sCD14 decreased significantly in treated HIV-infected subjects after a week of aspirin (median 2.60x106 vs 2.49x106 pg/mL;p<0.001) and in uninfected control subjects(median 1.26x106 vs1.04x106; p<0.009) (Figure 2C). T-cell activation correlated moderately with monocyte activation (r=0.43;p=0.06) (Figure 2D). These data demonstrate that HIV-infected subjects have increased levels of T-cell and monocyte activation, which subsequently decreases after a week of low-dose aspirin therapy. In this small study, there were no significant associations between aspirin-mediated improvement in T cell activation (CD4+HLADR+CD38+ or CD8+HLADR+CD38+) or monocyte activation and the following subject characteristics: age, gender, CD4 count, CD4 nadir, smoking status, years since HIV diagnosis, years on effective ART, or ART drug class (data not shown).
One week of aspirin enhances responsiveness of leukocytes to TLR agonist stimulation Innate immune cells are less responsive to Toll-like receptor (TLR) stimulation during chronic HIV-infection26,27, possibly as a result of chronic stimulation by inflammatory cytokines 26,28. Because aspirin is anti-inflammatory, we tested whether one week of aspirin therapy would improve leukocyte TLR-agonist responsiveness in HIV subjects. PBMCs from HIV-infected subjects on ART or uninfected control PBMCs were stimulated with relevant TLR 7, 9, and 4 agonists HIV, CpGB or LPS, respectively, for 18 hours and compared to un-stimulated PBMCs. After one week of aspirin therapy no differences were observed in mean spontaneous production of cytokines (IL-6, TNFa, IL-1ß, and IFNa) by PBMCs from HIV-infected subjects. However, in response to CpGB or HIV stimulation, after one week of aspirin PBMCs from HIV-infected subjects produced higher levels of IL-6 (mean 108.5 vs 92.8 ng/mL, p=0.01 and 107.6 vs 76.9 ng/mL, p=0.01 respectively), and a trend towards enhanced production of TNFa in response to CpGB or LPS (mean 11.3 vs 7.3 ng/mL, p=0.06 and 38.1 vs 24.1, p=0.07 respectively)(Figure 3). There were no improvements in TLR responsiveness after one week of aspirin of PBMCs from HIV-infected subjects to produce IL1ß or IFNa. In uninfected controls there was no significant change either in the spontaneous production of cytokines after overnight incubation or in response to TLR stimulation after one week of aspirin in the uninfected control PBMCs. For example, in response to CpGB or HIV stimulation, control PBMCs produced similar levels of IL-6 before and after aspirin (mean 73.8 vs 76.7 ng/mL, p=0.73 and 97.7 vs 107.3 ng/mL, p=0.57 respectively), and similar levels of TNFa in response to CpGB or LPS before and after aspirin (mean 8.7 vs 10.6 ng/mL, p=0.36 and 13.6 vs 13.3, p=0.85 respectively. Our data indicate that one week of low-dose aspirin 81 mg daily partly ameliorates the defect in TLR responsiveness in PBMCs from HIV-infected subjects.
One week of aspirin does not change soluble inflammation markers Markers of inflammation IL-6, d-dimer, and CRP are elevated in HIV disease, correlate with morbidity and mortality, and are somewhat reduced with ART, but remain elevated when compared with levels in HIV-uninfected persons 4,29-31. We investigated whether inflammatory markers decrease after a week of low dose aspirin therapy in treated HIV-infected patients. Median levels of CRP, d-dimer, and IL-6 decreased non-significantly after one week of aspirin therapy (2.7mg/L [0.8, 3.9] vs. 2.2 mg/L [0.8-3.2]), (0.23 mcg/mL [0, 0.36] vs. 0.13 mcg/mL [0, 0.38]), and 2.03 pg/mL [1.18, 2.31] vs. 1.98 pg/mL [1.15, 3.68]).
Plasma from HIV-infected subjects activates platelets and HIV-plasma activated plateletsactivate monocytes
To investigate the mechanism of platelet activation in HIV-infected subjects, we exposed platelets from healthy controls to plasma from our HIV-infected cohort. Contrary to results with healthy control plasma, plasma from our HIV-infected control cohort induced platelet activation, as assessed by increased surface expression of PAC-1 and P-selectin. Platelet activation after incubation with HIV-infected plasma was inhibited if the HIV plasma donor had received 1-week of daily aspirin. We next incubated the plasma-activated-platelets with THP-1 monocytes. We hypothesized that activated platelets contribute to monocyte activation in HIV disease. Platelets which were cultured with plasma from HIV-infected subjects were able to activate THP-1 monocytes, as evidenced by the formation of platelet monocyte aggregates. HIV-plasma-activated-platelets caused formation of platelet monocyte aggregates significantly more than healthy control-activated platelets. The formation of platelet monocyte aggregates in this assay was significantly abrogated by aspirin therapy, indicating that soluble plasma factors may play a role in platelet hyper reactivity and innate immune activation in HIV infection, which may be reversed by aspirin therapy (Figure 4).
Altogether we present new data that platelets from treated and virologically suppressed HIV-infected subjects are hyper-reactive spontaneously and in response to platelet-activating agonists. We show that one week of daily aspirin 81mg is effective in decreasing platelet activity in HIV-infected and uninfected controls. We also present the intriguing findings that aspirin may reverse immune activation in treated HIV infection and enhance leukocyte responses to TLR agonists. We show that platelets from healthy donors are activated by HIV plasma. In turn, HIV plasma-activated platelets contribute to monocyte activation, suggesting that soluble plasma factors in HIV-infected subjects play a role in platelet activation and secondarily in leukocyte activation. Moreover, increased platelet activation may contribute to immune activation, as both platelet and immune activation as both platelet and immune activation are ameliorated by aspirin therapy.
DISCUSSION
HIV-infected patients have a heightened risk of cardiovascular disease, including myocardial infarction and sudden cardiac death4,32,33 Although traditional cardiovascular risk factors and antiretroviral medications may contribute to this risk, emerging data suggests a role for immune activation and dysfunction. Multiple studies have shown that low CD4+ T cell counts are associated with cardiovascular events6,34 and increased immune activation has been associated with increased carotid artery lesions35. The link between immune activation and cardiovascular risk in HIV disease remains incompletely understood, but platelet activation may play an important role.
In this study we found that platelets from HIV-infected subjects are significantly more reactive spontaneously and to low-dose platelet activating agonists than are platelets from uninfected control subjects. At the highest doses of platelet activating agonists, however, platelets from both HIV-infected and uninfected control subjects aggregated maximally and no differences were observed. This data suggests that platelets from HIV-infected subjects have a lower threshold to activation, but that this hyper-reactivity is dose-dependent. When activated platelets are maximally stimulated with platelet agonists ex vivo, they demonstrate a blunted response, presumably related to the platelets having undergone intragranular release in vivo36. This phenomenon has been termed "exhausted platelets"37. In addition, as evidenced by ineffective platelet inhibition to AA and elevated urinary thomboxane metabolites after aspirin, COX-1 mediated platelet reactivity remains higher in patients with HIV than uninfected controls, suggesting that longer duration and/or higher dose of aspirin therapy may be needed to completely suppress COX-1 mediated platelet reactivity in ART-treated HIV-infected individuals.
One week of low-dose aspirin also decreased markers of T-cell and monocyte activation and augmented leukocyte responsiveness to certain TLR-agonist stimulants. Healthy platelets incubated with plasma from HIV-infected subjects became activated, however, plasma from HIV-infected subjects that had been taking aspirin for one week attenuated this platelet activation. Furthermore, HIV-plasma-activated-platelets potently activated monocytes, implicating a direct role for activated platelets in immune activation. Importantly, platelets incubated with HIV-plasma from subjects who had taken aspirin for one week had a significant reduction in monocyte activation. Therefore, activated platelets may contribute to monocye activaton in HIV infection. The close interaction between platelets and monocytes may help explain the relationship between platelet activity and inflammation, thereby providing a better understanding of the increased cardiovascular risk in HIV-infected subjects.
As an anti-platelet and immunomodulating agent, aspirin may diminish immune activation in HIV disease 1) indirectly, through inhibition of platelet activation and 2) directly, through blocking inflammatory pathways in multiple cell types. Platelets express toll-like receptor (TLR) 2, 4, and 938 and can become activated in response to pro-inflammatory cytokines or infective bacterial agents39,40, both of which are elevated in HIV infection. Platelets are anucleate; however, they contain a substantial amount of mRNA and all of the translational machinery necessary to rapidly generate their own proteins during hemostatic and inflammatory events. Activated platelets express CD154 (CD40L) and P-selectin which can in turn activate multiple cell types, including endothelial cells, neutrophils, monocytes, and dendritic cells, to produce inflammatory cytokines and chemokines41,42. The enhanced leukocyte responses we observed following aspirin use are consistent with prior reports. Aspirin has been shown to directly enhance TNFa release from LPS-activated RAW264.7 (macrophage) cells43. As observed in this study, aspirin therapy may reverse this inhibition of cytokine production by inhibiting platelet activation.
This small pilot study provides evidence that activated platelets may contribute to immune activation and inflammation in HIV infection. Importantly, this study also suggests that low-dose aspirin may be a potential intervention for HIV-infected subjects on ART to blunt platelet and immune activation and inflammation. As this study was a small non-randomized open-label pilot study, future studies are needed to confirm and expand upon our findings.
| |
| |
| |
|
|
|
